The reiteration of a Buy rating and maintenance of a $6 price target by Chardan Capital analyst Keay Nakae indicates a positive outlook for Arbutus Biopharma. This news is likely to have a positive short-term impact on the stock price, as it suggests that the analyst believes the company is undervalued and has potential for growth.